A new study published in the Journal of Rare Diseases shines a much-needed light on the lived experience of Pernicious Anaemia (PA). For many in our community, the findings won’t come as a surprise, but they provide vital academic validation for the daily struggles we face.
The research, led by Heidi Seage at Cardiff Met University, used in-depth interviews to map the “symptom journeys” of patients in the UK. Here is what the study tells us about the reality of living with PA:
1. The Long Road to Diagnosis
Participants described a “prolonged diagnostic uncertainty” that often lasted years. Before being heard, many were told their symptoms—ranging from unrelenting fatigue to “real fog” in the head—were simply psychological.
- Misattribution: GPs frequently defaulted to labels like depression or anxiety.
- Invisible Burden: Patients felt “disconnected” and “unheard,” struggling to explain that they weren’t just tired, but fundamentally ill.
2. Treatment Isn’t Always a “Cure”
While the UK standard of B12 injections (hydroxocobalamin) generally reduces symptom intensity, it often fails to eliminate them.
- The Treatment Gap: Many patients reported that symptoms return or intensify towards the end of their 8 to 12-week treatment cycle.
- Permanent Damage: For some, like “Elizabeth” in the study, delayed diagnosis led to irreversible nerve damage and chronic pain that persists despite treatment.
3. Taking Control through “Illness Literacy”
Faced with suboptimal treatment, the study found that patients are becoming “experts” in their own care.
- Self-Management: Up to 40% of patients may be self-medicating with non-prescribed injections to achieve better symptom control.
- Lifestyles Adjustments: Living with PA requires a “lifelong negotiation”. Participants described having to reduce social activities, exercise, and work commitments just to function.
“You can’t convey that to someone who’s never had it… being so emotional and so angry about the way you’re feeling and not being able to do anything about it.” — Helen, study participant
The Bottom Line for Advocates
This research underscores a clear need for patient-centred care. We are not just numbers on a blood test; we are individuals managing a complex, fluctuating condition.
The study concludes that healthcare models must move beyond just “medical management” and start supporting the broader psychosocial impact PA has on our lives. It’s time for shared decision-making regarding injection frequency and a genuine recognition of the patient as the expert in their condition.
This is why PAS, through our CEO who is currently chair of the B-12 Alliance, is driving forward the UK parliamentary reception which will be held later this year to turn the focus on empowering patients with the flexibility to self-administer B12 injections. By allowing patients to reclaim control over their health and tailor treatment frequency to their unique symptom patterns through a shift towards supported self-management, we can significantly improve a patient’s quality of life while reducing the administrative and clinical burden of routine appointments on the NHS.
However, true empowerment must be grounded in patient-centred care, ensuring that everyone—regardless of the cause of their deficiency—retains access to professional monitoring and the expert guidance necessary for safe, long-term health outcomes.
This is going to prove crucial and will help those with indisputably diagnosed PA.
That leaves those without that diagnosis relieved that the final sentence includes “… regardless of the cause of their deficiency” – as this simple inclusion could prevent them being trapped in limbo. Words do matter, and these few could significantly improve the lives of those who have so far been left behind and are not always included in surveys.
The impact on their lives has been the same, after all.